ABL1 and neoplasm: This reprogramming model would explain why targeted therapies focused on the oncogenes can fail in eliminating all cancer cells, in spite of their initial efficacy against the cells composing the main tumor mass; a good example of this apparent paradox is imatinib, that fails to kill BCR-ABL+ CSCs because somehow it cannot block the reprogramming capacity of the fusion oncogene in the stem cell compartment [15,18,19].